Live Breaking News & Updates on Sara mangsbo

Stay informed with the latest breaking news from Sara mangsbo on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Sara mangsbo and stay connected to the pulse of your community

Ultimovacs to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024 -April 04, 2024 at 01:00 am EDT

Oslo, April 4, 2024: Ultimovacs ASA , a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the TENDU-101 study in patients with...

United-states , Oslo , Norway , San-diego , California , Norwegian , American , Sara-mangsbo , American-association-for-cancer-research , Euronext-oslo-stock-exchange , Oslo-university-hospital , Cancer-research

Scientists analyze if T-cell tests can be used to determine whether people had COVID-19

Can T-cell tests be used to determine whether people have had COVID-19? Scientists at Uppsala University and Karolinska Institutet have jointly analysed this issue under the aegis of the COMMUNITY study at Danderyd Hospital. Their study is published in the scientific journal PLOS ONE.

Sweden , Danderyd , Stockholm , Ulrika , Ostergotland , Uppsala , Uppsala-lan , Karolinska-institutet , Sebastian-havervall , Peter-nilsson , Mia-phillipson , Emily-henderson

New model aims to promote better-adapted bladder cancer treatment in the future

New model aims to promote better-adapted bladder cancer treatment in the future
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

Sweden , Uppsala , Uppsala-lan , Swedish , Uno-malmstr , Ulrika-segersten , Sven-nelander , Anca-dragomir , Sara-mangsbo , Ilianak-kerzeli , Uppsala-university , Swedish-cancer-society

One in ten have long-term effects 8 months following mild COVID-19

Credit: Ludvig Kostyal
Eight months after mild COVID-19, one in ten people still has at least one moderate to severe symptom that is perceived as having a negative impact on their work, social or home life. The most common long-term symptoms are a loss of smell and taste and fatigue. This is according to a study published in the journal
JAMA, conducted by researchers at Danderyd Hospital and Karolinska Institutet in Sweden.
Since spring 2020, researchers at Danderyd Hospital and Karolinska Institutet have conducted the so-called COMMUNITY study, with the main purpose of examining immunity after COVID-19. In the first phase of the study in spring 2020, blood samples were collected from 2,149 employees at Danderyd Hospital, of whom about 19 percent had antibodies against SARS-CoV-2. Blood samples have since then been collected every four months, and study participants have responded to questionnaires regarding long-term symptoms and their impact on the quality of life.

Sweden , Danderyd , Stockholm , United-states , Uppsala , Uppsala-lan , American , Karolinska-institutet , Axel-rosell , Sebastian-havervall , Saram-mangsbo , Peter-nilsson

First patient dosed with therapeutic prostate cancer vaccine

First patient dosed with therapeutic prostate cancer vaccine
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Norway , Oslo , Wolfgang-lilleby , Sara-mangsbo , Oslo-university-hospital , Tetanus-epitope-targeting , Chief-innovation-officer , நோர்வே , ஒசிலோ , ஒசிலோ-பல்கலைக்கழகம்-மருத்துவமனை , தலைமை-கண்டுபிடிப்பு-அதிகாரி

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Norway , Oslo , Wolfgang-lilleby , Sara-mangsbo , Hans-vassg , Company-tetanus , Oslo-university-hospital , Tetanus-epitope-targeting , Oslo-university , Chief-innovation-officer , Ultimovac-tetanus-epitope-targeting , நோர்வே

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Norway , Oslo , Wolfgang-lilleby , Sara-mangsbo , Hans-vassg , Company-tetanus , Oslo-university-hospital , Tetanus-epitope-targeting , Oslo-university , Chief-innovation-officer , Ultimovac-tetanus-epitope-targeting

Interdisciplinary collaboration provides new answers about immunity after Covid-19

The COMMUNITY cohort comprises 2,149 employees at Danderyd Hospital
Photograph: Danderyd Hospital
Only weeks after the coronavirus reached Sweden, blood samples were taken from more than 2,000 employees at Danderyd Hospital. Today, a selection of the country’s leading researchers collaborate with this unique material within the COMMUNITY study to extract new knowledge needed to fight covid-19.
How long are we protected by antibodies after a covid-19 infection? And what will immunity look like over time? In a current collaboration, leading research environments at three Swedish universities and Danderyd Hospital seek answers to some of the most crucial questions surrounding the ongoing pandemic.

Sweden , Danderyd , Stockholm , Uppsala , Uppsala-lan , Swedish , Lars-hultman , Sophia-hober , Sara-mangsbo , Peter-nilsson , Mia-phillipson , Uppsala-university

New analysis method for predicting the risks and effects of immunotherapy

E-Mail
IMAGE: Sara Mangso is an Associate senior lecturer/Assistant Professor at the Department of Pharmaceutical Biosciences, Uppsala University
view more
Credit: Mikael Wallerstedt
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Immunotherapy - utilising the body's own immune system to combat tumour cells - is an area in which rapid progress is being made. Many new treatments are helping to increase survival rates among cancer patients, but more effective tools are still needed to predict how these drugs will affect an individual's immune system. In a new study at Uppsala University, researchers compared what happens when Rituximab monoclonal antibodies interact with the blood of healthy individuals and of patients with the disease that the monoclonal antibodies are intended to treat. The results showed that the immunological activation markers differ between the groups - an observation that could enable new scientific breakthroughs.

Sweden , Uppsala , Uppsala-lan , Swedish , Mattias-mattsson , Sara-mangsbo , Mark-cragg , Uppsala-university , Professor-of-experimental-cancer-research , University-of-southampton , Swedish-research-council , Department-of-pharmaceutical-biosciences

New analysis method could pave the way for important breakthroughs in immunotherapy

New analysis method could pave the way for important breakthroughs in immunotherapy
In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Immunotherapy - utilizing the body's own immune system to combat tumor cells - is an area in which rapid progress is being made. Many new treatments are helping to increase survival rates among cancer patients, but more effective tools are still needed to predict how these drugs will affect an individual's immune system. In a new study at Uppsala University, researchers compared what happens when Rituximab monoclonal antibodies interact with the blood of healthy individuals and of patients with the disease that the monoclonal antibodies are intended to treat. The results showed that the immunological activation markers differ between the groups - an observation that could enable new scientific breakthroughs.

Sweden , Uppsala , Uppsala-lan , Swedish , Mattias-mattsson , Sara-mangsbo , Mark-cragg , Emily-henderson , Uppsala-university , Professor-of-experimental-cancer-research , University-of-southampton , Swedish-research-council